Altogether, these results revealed that the FDA-approved drug orlistat could decrease EGFR palmitoylation and suppress its PM localization and evasion from lysosomal degradation in NAFLD. The gene discussed is EGFR; the disease is metabolic dysfunction-associated steatotic liver disease.